Alnylam Pharmaceuticals (ALNY) announced preliminary net product revenues for the fourth quarter and full-year 2024 for its approved products Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari (givosiran) and Oxlumo (lumasiran).The company also issued its net product revenue guidance for 2025 and outlined several key products and pipeline updates for the year.Both Onpattro and Amvuttra are approved for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.Givlaari is ap ...